DNTH insider trading
HealthcareDianthus Therapeutics, Inc. /DE/: insider trade history from SEC Form 4 filings.
About Dianthus Therapeutics, Inc. /DE/
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company's lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Company website: dianthustx.com
DNTH insider activity at a glance
FilingIQ tracks 122 insider transactions for DNTH in filings since Sep 13, 2023. The most recent transaction is dated Sep 17, 2026.
Across the full history, 7 open-market purchases
and 67 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on DNTH insider trades is 63.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest DNTH Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading DNTH
Frequently asked
- How many insider trades does FilingIQ track for DNTH?
- FilingIQ tracks 122 Form 4 insider transactions for DNTH (Dianthus Therapeutics, Inc. /DE/), covering filings from Sep 13, 2023 onwards. 47 of those are dated within the last 90 days.
- Are DNTH insiders net buyers or net sellers?
- Across the full Form 4 history for DNTH, 7 transactions (6%) were open-market purchases and 67 (55%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does DNTH insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is DNTH in?
- Dianthus Therapeutics, Inc. /DE/ (DNTH) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.08B.
Methodology & sources
Every DNTH insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.